{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-048785","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2023-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.102353+00:00","generated_at":"2026-06-10T13:22:33.695654+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Kintara Therapeutics enters into $2.85M ATM sales agreement with A.G.P.","bullets":["Up to $2.85M of common stock may be offered and sold from time to time via Agent A.G.P./Alliance Global Partners.","Agent receives 3.0% commission on gross proceeds; Company reimburses up to $50,000 in initial expenses.","Initially reserved 685,096 shares based on $4.16 closing price on Sep 15, 2023.","Sales may be made on Nasdaq Capital Market as 'at-the-market' under Rule 415; Company not obligated to sell."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-048785","json":"https://secwatch.observer/filing/0000950170-23-048785.json","markdown":"https://secwatch.observer/filing/0000950170-23-048785.md","text":"https://secwatch.observer/filing/0000950170-23-048785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023048785/0000950170-23-048785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023048785/ktra-20230919.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T13:22:33.695654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"199cc1c58a7e355fb9bf1e1d15f6229be047bf89","claim":"TuHURA Biosciences, Inc./NV entered into Sales Agreement with A.G.P./Alliance Global Partners valued at $2.85 million (effective 2023-09-19).","evidence_excerpt":"On September 19, 2023, Kintara Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $2.85 million (“Shares”), subject to certain limitations on the amount of Common Stock that may be offered and sold by the Company set forth in the Sales Agreement (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000095017023048785/0000950170-23-048785-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"$2.85 million"},{"label":"Effective","value":"2023-09-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}